Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.

MLA

Baumann, P., et al. “Amitriptyline Pharmacokinetics and Clinical Response: II. Metabolic Polymorphism Assessed by Hydroxylation of Debrisoquine and Mephenytoin.” International Clinical Psychopharmacology, vol. 1, no. 2, Apr. 1986, pp. 102–12. EBSCOhost, https://doi.org/10.1097/00004850-198604000-00002.

APA

Baumann, P., Jonzier-Perey, M., Koeb, L., Küpfer, A., Tinguely, D., & Schöpf, J. (1986). Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. International Clinical Psychopharmacology, 1(2), 102–112. https://doi.org/10.1097/00004850-198604000-00002

Chicago

Baumann, P, M Jonzier-Perey, L Koeb, A Küpfer, D Tinguely, and J Schöpf. 1986. “Amitriptyline Pharmacokinetics and Clinical Response: II. Metabolic Polymorphism Assessed by Hydroxylation of Debrisoquine and Mephenytoin.” International Clinical Psychopharmacology 1 (2): 102–12. doi:10.1097/00004850-198604000-00002.